Profil de DBV Technologies

Profil de la société

DBV Technologies compte 170 salariés et a son siège à Châtillon, France.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Description disponible en anglais.

Informations sur la société

Secteur

Santé

Industrie

Biotechnology

Pays

France

Siège

BAtiment IRO, 92320, Châtillon

Salariés

170

Cotation

DBV · Euronext Paris

Devise

EUR

ISIN

FR0010417345

Site web

dbv-technologies.com